InvestorsHub Logo
Followers 22
Posts 996
Boards Moderated 0
Alias Born 08/01/2016

Re: None

Tuesday, 11/22/2016 10:18:52 AM

Tuesday, November 22, 2016 10:18:52 AM

Post# of 462570
SATURDAY, DECEMBER 10, 2016 8.45 a.m OC60 - 9-Months and 12-Months Safety and Exploratory Efficacy Data of ANAVEX 2-73 in a Phase 2a Study
in Mild-to-Moderate Alzheimer’s Disease Patients
Stephen Macfarlane, MD1
, Marco Cecchi, PhD2
, Paul Maruff, PhD3
, Kristina M Kapiak4
, Christopher U Missling, PhD4
(1) Caulfield Hospital, Melbourne, Australia, (2) Neuronetrix, Louisville, KY, USA, (3) Cogstate Ltd., Melbourne, Australia, (4) Anavex Life Sciences Corp., New York, NY,
USA

http://www.ctad-alzheimer.com/sites/ctad.prod/files/files/PROGRAMfinal_CTAD2016_8nov%20.pdf
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News